Hospital Records Analysis of Vascular Access for Imuno and Chemotherapy

Introduction: Central venous access is essential for the administration of chemotherapy or immunotherapy in cancer treatment, with fully and semiimplantable devices associated with greater safety, comfort, and durability compared to other methods. Objective: To analyze hospital records regarding the implantation of fully and semi-implantable central venous catheters, assessing trends in hospitalization, costs, prevalence, and mortality. Methods: This was an observational, retrospective, and descriptive study using secondary data from the SUS Hospital Information System (SIH/SUS), extracted from DATASUS. The variables analyzed included the number of hospitalizations, average length of stay, total cost, prevalence rate and mortality rate. Results: Between 2008 and 2024, implantations increased by more than 600% (from 2,892 to 20,736 procedures), with the highest annual growth between 2022 and 2023. The average hospital stay reduced from 4.0 to 1.5 days. The total cost increased from US$273,583.43 to US$2,287,534.09. The prevalence increased from 1.5 to 8.7 per 1,000 hospitalizations, and mortality decreased from 2.56% to 0.89%, despite intermediate fluctuations. Conclusion: There was a significant increase in the implantation of central venous catheters for immunotherapy and chemotherapy in the SUS, with a reduction in hospital stay and mortality. Costs increased proportionally to the expansion of the procedure.